A Medical Device Daily
Biotronics3D (London) has worked with The Institute of Cancer Research (ICR; London) to develop and launch new software to significantly improve the accuracy of MRI scan analysis. Called 3D Net Perfusion, the system extracts data from images of tumors and transforms it into usable information.
A powerful analytical tool, 3D Net Perfusion enables clinicians to gain clearer comprehension of MRI scans, improving the accuracy of diagnosis and assessment of treatment efficacy. It is also a way of visualizing and measuring the blood supply to cancers – a crucial factor in tumor growth.
The software is the result of pioneering trials at the ICR led by Professor Martin Leach, David Collins and James d'Arcy, and is currently used in 10 research centers. Scientists from the ICR continue to work with Biotronics3D software developers to further enhance the product.
Paul Carnochan, Senior Business Development Manager at the ICR, believes the partnership could have broader implications and says: "London has an abundance of research capabilities and commercial expertise in the field of medical imaging and we believe that collaborations like this one can be the key to raising London's profile as a major biotech hub."
"Innovation carries risks and in fast moving markets such as global diagnostics it is important to leverage skills that exist outside the company through partnerships such as ours with the ICR," said Harry Hatzakis, CEO of Biotronics 3D.
The project has attracted significant investment from London-based venture specialist Longbow Capital.
Biotronics3D develops software applications for the diagnostic imaging industry.
Hyperbranch gets CE mark for NuSeal 100
HyperBranch Medical Technology (Durham, North Carolina) reported that it has received a CE mark for its NuSeal 100 dural sealant product. NuSeal 100 is used in cranial neurosurgical procedures where a water tight seal is required on the dura. NuSeal 100 is intended for direct application on the dural surfaces to provide a positive seal after suturing thereby minimizing risks associated with post-surgical CSF leaks.
The unique, single use device is terminally sterilized and sets on contact after a spray application. The synthetic, biocompatible composition is stored at room temperature and is delivered through the custom applicator to meet the specific needs of the procedure. The intended users of NuSeal 100 are Neurosurgeons in a surgical environment.
The company has also been developing advanced surgical sealants for pleural (lung), cardiovascular and hernia mesh fixation. These products are at various stages of clinical and pre-clinical development. The company also has licensed its ophthalmic sealant to BD Medical (Waltham, Massachusetts) for sale outside the U.S.